Want to join the conversation?
$MRK said that it's planning to submit a supplemental Biologics License Application (sBLA) to the U.S. FDA for KEYTRUDA (pembrolizumab) by the end of 2015 based on the findings from KEYNOTE-010 clinical trial. The company is also intending to submit a Marketing Authorization Application to the European Medicines Agency in early 2016.
Seems like $AMD has hit the right wind. Its stock was up almost 9% to $9.45 on Tuesday following reports that it signed a licensing deal with Intel.
$SBUX launched its annual “Starbucks for Life” competition in the U.S. and Canada. The winner of the competition will receive a credit of one drink or food item per day for a duration of 30 years.
$T shares rose 1.8%, as a big boost for the S&P 500. The company said its new streaming television service DirectTV has so far exceeded expectations.
$TXMD flying high.. anyone here to catch..?